Anti-CD38 monoclonal antibodies have become a central immunotherapeutic platform in multiple myeloma, where they have reshaped treatment across relapsed or refractory disease, frontline therapy, maintenance intensification, and minimal residual disease-oriented management. Their success in multiple myeloma has also sti...
Li-Ming Yu, Chang-Nian Li, Dadong Guo et al.· Frontiers in Immunology· 0 citations
Other primary malignancies (OPMs) may complicate diagnostic assessment, treatment sequencing, and prognostic evaluation in multiple myeloma (MM). This study characterized the spectrum and timing of OPMs and evaluated their association with overall survival (OS).
We retrospectively screened 461 unique patient...
Chang-Nian Li, Ya-Ru Wang, Lu-Lu Li et al.· Frontiers in Oncology· 0 citations
Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.
